A Look At Savara (SVRA) Valuation As MOLBREEVI Nears Key Regulatory Decisions In Rare Lung Disease

Savara (SVRA) is back in focus after regulators in Europe, the U.S. and the U.K. advanced reviews of its lead drug candidate MOLBREEVI for autoimmune pulmonary alveolar proteinosis, a rare chronic lung disease.

See our latest analysis for Savara.

At a share price of $5.46, Savara has seen an 8.12% 1 day share price return after the regulatory update, while its 1 year total shareholder return of 90.91% and 3 year total shareholder return of 219.30% signal strong longer term momentum despite recent 30 and 90 day share price declines.

If you are looking for other names tied to similar themes around data, automation and next generation platforms, this is a good moment to scan 33 robotics and automation stocks

With shares at US$5.46, a market value of about US$1.28b and no approved products yet, the key question is whether recent regulatory milestones leave meaningful upside or if the market is already pricing in future growth.

Preferred price to book of 6.8x: Is it justified?

At a last close of $5.46, Savara trades on a P/B of 6.8x, which is high relative to the wider US biotech industry but lower than its closer peer set.

P/B compares a company’s market value to its book value, which is essentially net assets on the balance sheet. For early stage biopharma with little or no revenue and ongoing losses, investors often focus on P/B when traditional earnings based metrics like P/E are not meaningful.

Analysts currently see Savara as unprofitable, with a reported net loss of $118.84m and no meaningful revenue. The 6.8x P/B therefore suggests the market is placing a sizeable value on the company’s pipeline and future cash flow potential rather than current financial results.

Against the broader US biotechs industry average of 2.1x, Savara’s 6.8x P/B screens as expensive, which aligns with the view that the market is already pricing in a significant amount of success. However, compared with a peer average P/B of 24.8x, the same 6.8x looks restrained and implies investors are less aggressively valuing Savara than some of its closest comparables.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price to book of 6.8x (ABOUT RIGHT)

However, there is still execution risk around regulatory decisions and trial outcomes. Any delay or setback could weigh on sentiment at a P/B of 6.8x.

Find out about the key risks to this Savara narrative.

Next Steps

With sentiment clearly mixed after a huge run and premium P/B, it makes sense to check the data now and decide where you stand. Start with the 1 key reward and 2 important warning signs.

Looking for more investment ideas?

If you stop with just one stock on your radar, you risk missing other opportunities that could fit your goals even better, so broaden your search confidently now.

• Hunt for quality at a discount by checking companies in the 58 high quality undervalued stocks that pair solid fundamentals with appealing prices.
• Secure more reliable income streams by scanning the 12 dividend fortresses and focusing on businesses with higher yields and resilience.
• Sleep a little easier by reviewing the 64 resilient stocks with low risk scores that highlight businesses with more resilient risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com